Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson(The University of Texas MD Anderson Cancer Center), John M. Bennett(The University of Texas MD Anderson Cancer Center), Kenneth J. Kopecky(The University of Texas MD Anderson Cancer Center), Thomas Büchner(The University of Texas MD Anderson Cancer Center), Cheryl L. Willman(The University of Texas MD Anderson Cancer Center), Elihu H. Estey(The University of Texas MD Anderson Cancer Center), Charles A. Schiffer(The University of Texas MD Anderson Cancer Center), Hartmut Doehner(The University of Texas MD Anderson Cancer Center), Martin S. Tallman(The University of Texas MD Anderson Cancer Center), Tim Lister(The University of Texas MD Anderson Cancer Center), Francesco Lo‐Coco(The University of Texas MD Anderson Cancer Center), Roel Willemze(The University of Texas MD Anderson Cancer Center), Andrea Biondi(The University of Texas MD Anderson Cancer Center), Wolfgang Hiddemann(The University of Texas MD Anderson Cancer Center), Richard A. Larson(The University of Texas MD Anderson Cancer Center), Bob Löwenberg(The University of Texas MD Anderson Cancer Center), Miguel Á. Sanz(The University of Texas MD Anderson Cancer Center), David R. Head(The University of Texas MD Anderson Cancer Center), R Ohno(The University of Texas MD Anderson Cancer Center), Clara D. Bloomfield(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Oncology
December 12, 2003
Cited by 2,661

Abstract

An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials. Since the original publication, there have been major advances in our understanding of the biology and molecular genetics of acute leukemia that are clinically relevant and warrant incorporation into response definitions. Differences from the 1990 recommendations included a category of leukemia-free state, new criteria for complete remission, including cytogenetic and molecular remissions and remission duration. Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders.


Related Papers

No related papers found

Powered by citation graph analysis